AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Business & Industry
- Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)
- Boehringer Ingelheim (Canada) Ltd. and IBM Canada announce first of its kind collaboration to integrate blockchain technology into clinical trials
- Merz delivers double-digit growth in strategic business areas
- The Union for International Cancer Control and Pfizer announce new phase of global grants initiative supporting metastatic breast cancer patients
- Merck to expand US biopharmaceutical R&D facility to advance innovative clinical pipeline
Research & Development
- Researchers develop reversible antiplatelet therapy to fight clotting, cancer metastasis
- How Viagra puts a brake on a master growth regulator to treat heart disease
- Nano drops a million times smaller than a teardrop explodes 19th century theory
- New insight into cell receptors opens the way for tailored cancer drugs
- New pill can deliver insulin
- Simple drug combination creates new neurons from neighboring cells
- Cannabinoid compounds may inhibit growth of colon cancer cells
Conferences & Events
- eyeforpharma Barcelona Conference, Expo & Awards 2019
- SMi presents the 2nd Annual Conference: Injectable Drug Delivery 2019
- 21st Annual Superbugs & Superdrugs Conference
- SMi Group announces the 10th Annual RNA Therapeutics Conference
- Pre-Filled Syringes & Injectable Drug Devices Europe 2018
- Social Media in the Pharmaceutical Industry Conference 2019
- Lyophilization USA Conference 2018
Regulatory Affairs
- FDA takes new steps to adopt more modern technologies for improving the security of the drug supply chain
- FDA takes action against 17 companies for illegally selling products claiming to treat Alzheimer's disease
- FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder
- FDA approves first generic Advair Diskus
- FDA approves first treatment for rare blood disease